This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Exact Sciences Toekomstige groei
Future criteriumcontroles 3/6
Exact Sciences zal naar verwachting groeien in winst en omzet met respectievelijk 52.3% en 9.1% per jaar. De winst per aandeel zal naar verwachting groeien met 52% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 15.1% zijn.
Belangrijke informatie
52.3%
Groei van de winst
52.03%
Groei van de winst per aandeel
| Biotechs winstgroei | 25.3% |
| Inkomstengroei | 9.1% |
| Toekomstig rendement op eigen vermogen | 15.13% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 24 Mar 2026 |
Recente toekomstige groei-updates
Recent updates
Analyse-update • Mar 16
EXAS: Abbott Deal Expectations And Downgrades Will Shape Event Path Forward
The analyst price target for Exact Sciences has been adjusted to reflect a revised view of slightly higher long term revenue growth and profit margins, along with a modestly higher discount rate and a lower assumed future P/E multiple, resulting in a new target of $105.81, unchanged from the prior target of $105.81. Analyst Commentary Recent Street research around Exact Sciences has been limited, with one identified change being a downgrade and another reference tied to a broader sector view rather than company specific fundamentals.
Analyse-update • Mar 02
EXAS: Fair Value Reset Will Hinge On Abbott Deal And Margin Delivery
Analysts have trimmed their fair value estimate for Exact Sciences from $116.46 to $112.11. This reflects slightly lower modeled revenue growth, offset by a modestly higher profit margin outlook and a reduced future P/E assumption.Analyse-update • Feb 16
EXAS: Abbott Takeout Price And Downgrades Will Shape Event Path Forward
Analysts have maintained their $105 per share price target for Exact Sciences, with recent research emphasizing the agreed Abbott acquisition price of $105 as the key anchor for valuation and indicating limited expectations for additional upside. Analyst Commentary Recent research around Exact Sciences has shifted sharply toward viewing the agreed US$105 per share Abbott offer as the primary reference point for valuation, with many firms recalibrating their ratings and targets to that level.Analyse-update • Feb 02
EXAS: Takeout Premium And Downgrades Will Frame Upcoming Deal Closure Risk
Analysts made a modest upward adjustment to their fair value estimate for Exact Sciences to $105.81, describing it as largely in line with the $105 per share Abbott takeout price and supported by updated assumptions around discount rate, profit margin, and future P/E in recent research following the wave of rating downgrades tied to the announced acquisition. Analyst Commentary Street research around Exact Sciences has shifted quickly toward treating the shares as a deal proxy after the announced US$105 per share cash offer from Abbott.Analyse-update • Jan 19
EXAS: Abbott Takeover Agreement Will Anchor Upside To Deal Completion
Analysts have lifted their fair value estimate for Exact Sciences from $77.68 to $116.46. This reflects updated assumptions around slightly higher revenue growth, a revised profit margin outlook, a modestly higher discount rate, and a higher future P/E multiple in light of the agreed Abbott takeout price of $105 per share and the cluster of Street targets around that level.
Analyse-update • Jan 04
EXAS: Abbott Deal At $105 Will Define Shares With Balanced Prospects
Analysts have raised their price target on Exact Sciences to approximately $93 from about $48, citing the $105 per share Abbott takeout as validation of higher long term profitability and valuation multiples, despite slightly tempered standalone growth expectations. Analyst Commentary Bearish analysts largely framed the Abbott transaction as crystallizing value and limiting further upside, prompting a wave of rating downgrades to Hold, Neutral, Equal Weight, and Market Perform.Analyse-update • Dec 15
EXAS: Takeout Premium Will Shift Focus To Deal Completion Risk Balancing Upside
Analysts have raised their price targets on Exact Sciences toward the agreed Abbott takeout price of $105 per share. This reflects improved growth and margin expectations alongside the belief that the acquisition premium fairly captures the company’s long term value.Analyse-update • Dec 01
EXAS: Acquisition By Abbott Will Shift Focus Toward Deal Closure And Approval
The analyst price target for Exact Sciences has increased from $82.10 to $103.67 following the announcement of its acquisition by Abbott for $105 per share. Analysts cite the takeover premium and strong strategic rationale as key drivers behind the upward revision.Seeking Alpha • Nov 20
Abbott To Complete $21B M&A Deal For Exact Sciences - What Investors Should Know
Summary Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue growth, record Q3 results, and promising new products like CancerGuard but remains unprofitable with fierce competition in cancer screening. Abbott Laboratories seeks to revitalize growth and expand its diagnostics portfolio, betting on Exact Sciences' MCED technology and established products like Cologuard despite high acquisition costs. Maintain Hold ratings on both Exact Sciences and Abbott Laboratories; Exact shareholders benefit from the deal, while Abbott's upside depends on successful integration and MCED market adoption. Read the full article on Seeking AlphaAnalyse-artikel • Nov 20
Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 37% But Its Business Prospects Need A Lift Too
Despite an already strong run, Exact Sciences Corporation ( NASDAQ:EXAS ) shares have been powering on, with a gain of...Analyse-update • Nov 17
EXAS: Revenue Momentum And Expanded Guidance Will Drive Shares Higher
Analysts have raised their price target for Exact Sciences from approximately $70 to $82, citing stronger-than-expected revenue growth, margin expansion, and several upward revisions in expectations following earnings. Analyst Commentary Recent analyst updates reflect growing optimism about Exact Sciences' prospects, particularly in light of strong revenue growth, expanded guidance, and successful execution across its core business lines.Analyse-update • Nov 01
EXAS: Cancer Screening Expansion Will Balance Challenges From Blood Test Data
Analysts have raised their price target for Exact Sciences to $70 from $60, citing continued strength in its core Cologuard franchise as well as expanding opportunities in cancer screening and detection. Analyst Commentary Recent analyst activity for Exact Sciences reflects a dynamic mix of optimism and caution, as the company continues to execute on its core strengths while navigating evolving market expectations.Analyse-update • Oct 18
Humana, Centene And Medicare Coverage Will Increase Screening Access
Analysts have raised their price target for Exact Sciences to approximately $70 from $65, citing strong momentum from new revenue opportunities and increased confidence in long-term growth drivers. Analyst Commentary Recent analyst actions on Exact Sciences reflect notable shifts in sentiment, both positive and cautious, following the company’s latest performance and strategic moves.Analyse-update • Oct 03
Humana, Centene And Medicare Coverage Will Increase Screening Access
Analysts have modestly raised their price target for Exact Sciences, increasing it from $64.01 to $65.38. They cite incremental near-term revenue growth drivers, ongoing margin expansion, and improved cash flow prospects as key reasons for the upward adjustment.Analyse-update • Sep 12
Humana, Centene And Medicare Coverage Will Increase Screening Access
Analysts have modestly raised Exact Sciences’ price target to $64.01, citing renewed optimism from the Freenome deal and Shield V2 data as potential growth catalysts despite near-term skepticism around CRC blood-test data, resulting in only a slight upward revision to fair value. Analyst Commentary Bullish analysts cite the Freenome deal and Shield V2 data as catalysts for renewed Street focus on execution, with multiple near-term revenue growth drivers, continued EBITDA margin expansion, improving cash flow, and possible estimate upside.Analyse-artikel • Sep 08
Exact Sciences Corporation's (NASDAQ:EXAS) Price Is Right But Growth Is Lacking After Shares Rocket 31%
Exact Sciences Corporation ( NASDAQ:EXAS ) shareholders are no doubt pleased to see that the share price has bounced...Analyse-update • Aug 08
Humana, Centene And Medicare Coverage Will Increase Screening Access
Despite a slight rise in Exact Sciences’ future P/E ratio and a modest decline in its net profit margin, the consensus analyst price target remains unchanged at $64.60. What's in the News Exact Sciences raised full-year 2025 revenue guidance to $3.13–$3.17 billion, up from previous estimates of $3.07–$3.12 billion, reflecting strong business momentum (Key Developments, 2025-08-06).
Nieuwe analyse • Apr 27
Cologuard Plus And Oncodetect Will Improve Cancer Screening Outcomes
Cologuard Plus and rescreening efforts are key drivers of revenue growth, bolstered by payer coverage and an increasing pool of eligible individuals.Seeking Alpha • Aug 18
Exact Sciences: Cost Optimization And Product Strength
Summary Exact Sciences stock is down 35% since August 2021, now trading at around $58.75. The second quarter of 2024 (Q2) results beat expectations with revenue growth driven by the Cologuard screening segment. It raised adjusted EBITDA guidance for 2024, demonstrating confidence in continued sales momentum and profitability. It is likely to suffer from volatility risks as it continues to strike a balance between growth and profitability. The stock is a buy with a potential 27% upside also given the way it is improving its competitive position and leveraging AI for accelerating data analysis. Read the full article on Seeking AlphaSeeking Alpha • Jun 11
Exact Sciences: Still No Reason To Own
Summary We are revisiting oncology testing company Exact Sciences Corporation today for the first time in nearly a year and a half. The shares have been cut by more than half since last summer, despite revenue growth in the low teens and strong support from the analyst firm community. Is it time to buy the dip? An updated analysis around Exact Sciences follows in the paragraphs below. Read the full article on Seeking AlphaWinst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 4,491 | 341 | 694 | 933 | 7 |
| 12/31/2027 | 4,107 | 248 | 327 | 757 | 10 |
| 12/31/2026 | 3,661 | 35 | 99 | 534 | 12 |
| 12/31/2025 | 3,247 | -208 | 357 | 491 | N/A |
| 9/30/2025 | 3,082 | -987 | 247 | 387 | N/A |
| 6/30/2025 | 2,940 | -1,005 | 170 | 306 | N/A |
| 3/31/2025 | 2,828 | -1,020 | 194 | 324 | N/A |
| 12/31/2024 | 2,759 | -1,029 | 75 | 211 | N/A |
| 9/30/2024 | 2,692 | -214 | 98 | 233 | N/A |
| 6/30/2024 | 2,612 | -175 | -15 | 119 | N/A |
| 3/31/2024 | 2,535 | -240 | -20 | 112 | N/A |
| 12/31/2023 | 2,500 | -204 | 32 | 156 | N/A |
| 9/30/2023 | 2,406 | -282 | -24 | 139 | N/A |
| 6/30/2023 | 2,301 | -432 | -108 | 73 | N/A |
| 3/31/2023 | 2,200 | -517 | -298 | -88 | N/A |
| 12/31/2022 | 2,084 | -624 | -438 | -224 | N/A |
| 9/30/2022 | 2,005 | -716 | -443 | -300 | N/A |
| 6/30/2022 | 1,938 | -735 | -437 | -300 | N/A |
| 3/31/2022 | 1,852 | -745 | -330 | -199 | N/A |
| 12/31/2021 | 1,767 | -596 | -238 | -102 | N/A |
| 9/30/2021 | 1,760 | -793 | -117 | 34 | N/A |
| 6/30/2021 | 1,712 | -829 | 30 | 156 | N/A |
| 3/31/2021 | 1,546 | -720 | 19 | 109 | N/A |
| 12/31/2020 | 1,491 | -824 | 71 | 136 | N/A |
| 9/30/2020 | 1,321 | -327 | -89 | 0 | N/A |
| 6/30/2020 | 1,131 | -165 | -238 | -111 | N/A |
| 3/31/2020 | 1,062 | -136 | -262 | -87 | N/A |
| 12/31/2019 | 876 | -213 | -284 | -112 | N/A |
| 9/30/2019 | 724 | -216 | N/A | -88 | N/A |
| 6/30/2019 | 623 | -221 | N/A | -62 | N/A |
| 3/31/2019 | 526 | -219 | N/A | -105 | N/A |
| 12/31/2018 | 454 | -175 | N/A | -69 | N/A |
| 9/30/2018 | 399 | -143 | N/A | -69 | N/A |
| 6/30/2018 | 353 | -124 | N/A | -70 | N/A |
| 3/31/2018 | 308 | -119 | N/A | -77 | N/A |
| 12/31/2017 | 266 | -114 | N/A | -72 | N/A |
| 9/30/2017 | 214 | -130 | N/A | -98 | N/A |
| 6/30/2017 | 169 | -141 | N/A | -118 | N/A |
| 3/31/2017 | 133 | -155 | N/A | -121 | N/A |
| 12/31/2016 | 99 | -167 | N/A | -130 | N/A |
| 9/30/2016 | 79 | -170 | N/A | -133 | N/A |
| 6/30/2016 | 63 | -175 | N/A | -145 | N/A |
| 3/31/2016 | 50 | -169 | N/A | -141 | N/A |
| 12/31/2015 | 39 | -158 | N/A | -134 | N/A |
| 9/30/2015 | 27 | -150 | N/A | -135 | N/A |
| 6/30/2015 | 14 | -139 | N/A | -119 | N/A |
| 3/31/2015 | 6 | -120 | N/A | -104 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Er wordt voorspeld dat EXAS de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 3.4% ).
Winst versus markt: Er wordt verwacht dat EXAS de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.
Hoge groeiwinsten: Er wordt verwacht dat EXAS binnen 3 jaar winstgevend zal worden.
Omzet versus markt: De omzet van EXAS ( 9.1% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.6% per jaar).
Hoge groei-inkomsten: De omzet van EXAS ( 9.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen EXAS zal naar verwachting over 3 jaar laag zijn ( 15.1 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/03/24 00:21 |
| Aandelenkoers aan het einde van de dag | 2026/03/20 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Exact Sciences Corporation wordt gevolgd door 27 analisten. 12 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Bruce Jackson | Benchmark Company |
| Raymond Myers | Benchmark Company |